Key Takeaways
- UnitedHealth delivered Q2 adjusted earnings of $6.38 per share, significantly exceeding the consensus estimate of $4.91
- Quarterly revenue reached $112 billion, surpassing analyst expectations of $110.8 billion
- The medical loss ratio improved to 86.7%, compared to 89.4% in the prior-year period
- Management elevated full-year adjusted earnings guidance to $19.50–$20.00, above the previous range starting at $18.25
- Baird analyst upgraded UnitedHealth from Sell to Hold, increasing the price target from $287 to $453
Shares of UnitedHealth (UNH) climbed approximately 8% Thursday following the healthcare giant’s second-quarter earnings report, which featured adjusted earnings per share of $6.38—well ahead of the $4.91 Wall Street consensus. The company’s quarterly revenue of $112 billion also exceeded analyst projections of $110.8 billion.
UnitedHealth Group Incorporated, UNH
Prior to the earnings release, the stock had already climbed roughly 27% year-to-date. The quarterly results delivered exactly what market participants were hoping to see: consecutive quarters demonstrating effective medical cost management.
The most critical metric investors were tracking was the medical loss ratio, which registered at 86.7%—a notable decline from 89.4% in the same quarter last year and superior to Wall Street’s 88.4% projection. This lower percentage indicates the insurer retains a larger portion of premium income.
Company executives attributed the positive trend to “product design changes, improved medical management, and better aligned pricing” initiatives.
UnitedHealth elevated its full-year adjusted earnings per share forecast to a range of $19.50 to $20.00, up from the prior guidance floor of $18.25. The Street had been anticipating $18.49.
Health Insurance Peers Also Advanced
The positive momentum extended beyond UNH. Shares of Humana (HUM) and CVS Health—parent company of insurance arm Aetna—both gained approximately 1% in early trading. These three major players all maintain significant positions in Medicare Advantage, a segment that has faced challenges from rising medical expenses.
UnitedHealth has strategically reduced its Medicare Advantage footprint to safeguard profit margins. The organization now projects full-year Medicare Advantage enrollment will decrease by approximately 1.1 million members.
Tim Noel, CEO of UnitedHealthcare, indicated during the earnings call that Medicare cost trends are “still running well above historical levels, but below our expectations so far in 2026.” He highlighted benefit restructuring and enhanced care management approaches as key factors.
Raymond James analyst John Ransom characterized the quarter as “a strong 2Q” that was “widely expected” and suggested it “should be good enough to keep the rally going.”
Wells Fargo’s Stephen Baxter noted that “UNH’s momentum exiting 2Q26 appears quite strong.”
Baird Raises Rating While Noting Future Challenges
Friday saw UNH shares gain an additional 3% after Baird analyst Michael Ha upgraded the rating to Hold from Sell while raising the price objective to $453 from $287. Ha pointed to increasing confidence in near-term Medicare Advantage margin expansion and moderating healthcare utilization trends.
His examination of industry metrics indicates Medicare Advantage utilization has moderated this year, with evidence of “flatter provider coding intensity growth.” Should this pattern persist, it could support margin improvement in Medicare Advantage through 2027.
Ha expressed ongoing reservations about Optum Health’s ability to achieve its stated 6%–8% long-term margin objective, particularly given possible challenges from anticipated Medicare Advantage risk adjustment model modifications expected in early 2027.
He also highlighted concerns regarding Optum Insight, pointing to margin inconsistency, limited backlog transparency, and uncertainties surrounding customer retention rates.
The consensus rating from Wall Street analysts on UNH stands at Strong Buy, comprising 19 Buy recommendations and four Hold ratings. The mean price target of $450.91 suggests approximately 4% upside potential from present trading levels.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
